Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.
The platform, EchoGo Amyloidosis, uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart.
myBinderRelated Content
-
Transthyretin Cardiac Amyloidosis in Black AmericansTransthyretin-related cardiac amyloidosi...
-
Van Selby, MDDr. Van Selby is a cardiologist who spec...
-
New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac AmyloidosisSystemic amyloidoses are rare and protei...
-
AL Amyloidosis and the Heart by Dr. Tony Urey – ASG Webinar – 5/9https://www.youtube.com/watch?v=vP4wvJq5...
-
Senile Systemic Amyloidosis: Clinical Features at Presentation and OutcomeBACKGROUND: Cardiac amyloidosis is a fa...
-
Cardiac Amyloidosis Diagnostic Workuphttps://www.youtube.com/watch?v=gaWfWCph...
-
Frederick L. Ruberg, MDFrederick L. Ruberg, MD is an Associate ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
